Takeda
Clinical trials sponsored by Takeda, explained in plain language.
Global pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New tool helps predict Crohn's Flare-Ups years in advance Results expected Sep 2026 (estimated)
- Spain launches nationwide narcolepsy count Results expected Sep 2026 (estimated)
- New narcolepsy drug TAK-861 put to the test in withdrawal trial Results expected Oct 2026 (estimated)
- New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder Results expected Oct 2026 (estimated)
- New hope for rare blood disorder: study reviews real-world use of enzyme therapy Results expected Oct 2026 (estimated)
-
New hope for kidney transplant patients: drug targets rejection
Disease control Not yet recruitingThis study tests a drug called mezagitamab in people who have had a kidney transplant and are experiencing a type of rejection called antibody-mediated rejection (AMR). AMR happens when the body's immune system attacks the donor kidney, which can lead to kidney failure. The study…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a weekly shot bring antibody levels to safety in untreated immune deficiency?
Disease control Not yet recruitingThis trial tests whether TAK-664, an antibody replacement given under the skin, can quickly raise and maintain protective IgG levels in people with primary immunodeficiency who have never received antibody therapy. Participants receive daily doses for 5 days, then a dose on day 8…
Phase 4 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a pill clear psoriasis on hands and feet?
Disease control Not yet recruitingThis trial tests whether an oral medication called zasocitinib (TAK-279) can reduce the redness, thickening, scaling, and painful cracks of palmoplantar psoriasis, a type of psoriasis that affects the palms and soles. Adults with moderate-to-severe non-pustular palmoplantar psori…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a hormone mimic curb the need for bloodletting in a blood cancer?
Disease control Not yet recruitingThis trial tests whether rusfertide, a synthetic version of the hormone hepcidin, can help people with polycythemia vera—a condition where the bone marrow makes too many red blood cells—by lowering iron availability and keeping red blood cell counts in check. The study enrolls Ch…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Takhzyro under the microscope: Real-World safety check for rare swelling disease
Disease control Not yet recruitingThis study looks at how safe and effective Takhzyro is for teenagers and adults with hereditary angioedema (HAE) in everyday medical care in South Korea. HAE is a rare condition that causes sudden swelling under the skin or inside the body. The study will track side effects and h…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare blood disorder: study reviews real-world use of enzyme therapy
Knowledge-focused Not yet recruitingThis study looks back at medical records of people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare inherited blood disorder that causes dangerous blood clots. Participants received a manufactured version of the missing ADAMTS13 enzyme through an early access pr…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Study examines which IBD drugs are safer for seniors
Knowledge-focused Not yet recruitingThis study looked at nearly 24,000 older adults (65+) with ulcerative colitis or Crohn's disease to see if certain advanced treatments lead to more infections. Researchers compared patients taking ENTYVIO, TNF-alpha inhibitors, or ustekinumab using Medicare claims data from 2016 …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
New study tracks Real-World impact of fruquintinib on advanced colon cancer
Knowledge-focused Not yet recruitingThis study will follow 110 adults in Poland with metastatic colorectal cancer (cancer that has spread) who are taking fruquintinib after at least two prior treatments. Researchers will track how long patients live without their cancer getting worse and their overall survival, usi…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Egyptian HAE patients to be studied for better care insights
Knowledge-focused Not yet recruitingThis study will collect information from medical records and routine clinic visits of 100 people in Egypt with hereditary angioedema (HAE) type I or II. The goal is to understand how the condition is diagnosed and managed in current medical practice. No new treatments are being t…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Do patients understand their home infusion guides? new survey aims to find out
Knowledge-focused Not yet recruitingThis survey will ask about 60 people—patients with Gaucher disease, their caregivers, and home infusion nurses—how well they understand and use educational materials for at-home VPRIV infusions. The materials include an infusion diary, a guide, and an emergency plan. The goal is …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC